Tarlatamab  (Synonyms: AMG-757)

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research^[1].

Tarlatamab (AMG-757; 0-10 nM; 48 hours) has potent, specific cytotoxic activity against DLL3-expressing SCLC cell lines in vitro^[1].
Tarlatamab (0-10 nM; 4-72 h) increased granzyme B levels and cytotoxicity over time, with maximal signal observed at 48 hours. Markers of T-cell activation or inflammation, CD69, CD71, PD-1, and PD-L1 (37-39) were upregulated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tarlatamab (AMG-757; 3 mg/kg; IP; once weekly for 3 weeks) drives tumor regression in mouse models of SCLC^[1].
Tarlatamab (IP; 12 μg/kg; single dose) has a mean half-life of 234 hours (9.8 days), a mean clearance of 0.487 mL/hour/kg and a steady-state volume of distribution of 146 mL/kg in nonhuman primates (NHPs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2307488-83-9

Liquid

Colorless to light yellow

[Tarlatamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michael J Giffin, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537.  [Content Brief]